Quantitative analysis for Climb Bio, Inc. (CLYM) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (62.0) (grade B). Gem alpha score: 43.0. 29 signals analyzed (24 differentiated alt-data).
CLYM stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $9.34 | $8.75 | $8.78 |
| 2026-05-11 | $12.48 | $11.09 | $11.12 |
| 2026-05-21 | $11.04 | $10.39 | $10.91 |
| 2026-06-03 | $11.34 | $10.36 | $10.44 |
| 2026-06-15 | $11.87 | $11.27 | $11.49 |
| 2026-06-26 | $13.16 | $12.42 | $13.08 |
| 2026-07-09 | $13.94 | $13.13 | $13.82 |
| 2026-07-21 | $13.20 | $12.28 | $13.10 |
| 2026-07-31 | $12.25 | $11.45 | $11.90 |
| 2026-08-12 | $14.55 | $13.61 | $14.39 |
| 2026-08-24 | $17.41 | $16.05 | $16.40 |
| 2026-09-03 | $15.39 | $13.60 | $14.59 |
How Climb Bio, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| BBOT | BridgeBio Oncology Therapeutics Inc. | $706M | — |
| ANRO | Alto Neuroscience, Inc. | $729M | — |
| TLRY | Tilray Brands, Inc. | $647M | — |
| SPTX | Seaport Therapeutics, Inc. Common Stock | $837M | — |
View all Health Care stocks by valuation and signals →
Climb Bio, Inc. (CLYM) scores Buy (62.0), and the composite conceals a 53-point disagreement between its dimensions. It is strongest on analyst consensus at 88 and competitive moat at 87, and weakest on AI Alpha (gem) at 35. A stock can carry analyst consensus that high while AI Alpha (gem) sits at 35; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 88 |
| competitive moat | 87 |
| valuation | 72 |
| technicals | 53 |
| earnings quality | 42 |
| AI Alpha (gem) | 35 |
StoQuant analyzes 29 signals (24 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Climb Bio, Inc. (CLYM): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CLYM"><img src="https://stoquant.com/badge/CLYM.svg" alt="Climb Bio, Inc. (CLYM) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.